Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated poliomyelitis vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The inactivated poliomyelitis vaccine (Salk strain), also known as Salk IPV or cIPV, is a trivalent biologic vaccine containing inactivated (killed) wild-type poliovirus types 1 (Mahoney), 2 (MEF-1), and 3 (Saukett). It is produced by growing the viruses in cell cultures, such as Vero or human diploid cells, and inactivating them with formaldehyde. Unlike the oral polio vaccine (OPV), IPV does not contain live virus and therefore carries no risk of vaccine-associated paralytic poliomyelitis (VAPP). It is administered via intramuscular or intradermal injection and induces systemic humoral immunity, preventing the virus from spreading to the central nervous system and causing paralysis. Modern versions are often referred to as enhanced IPV (eIPV) due to their higher antigen content compared to original formulations.
- Brand names
- IPOLImovax Polio
- Other names
- Salk IPVcIPVeIPVenhanced inactivated poliovirus vaccineconventional inactivated poliovirus vaccineSalk-strain inactivated poliovirus vaccine
Beyond the preview
Go deeper on inactivated poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated poliomyelitis vaccine.